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All the components of the renin-angiotensin system have been identified in the heart including the angiotensin II receptor
subtypes AT, and AT^
In the normal human heart, there is a decreasing receptor density from the right atrium to the left ventricle. In right atrial
membranes prepared from pathological hearts, the percentage of AT, receptor decreases with the severity of cardiac dys-
function whereas that of AT2 receptor increases. Treatment of hypertrophic rats with AT, receptor antagonists inhibits car-
diac hypertrophy and reverses the increase receptor density, indicating involvement of this Ang II receptor subtype. The role
of the AT2 receptor b still largely unknown but it may be involved in cell growth and proliferation. The cloning of both AT,
and AT2 receptors as well as the availability of potent and selective antagonists will help us to understand better the func-
tional role of Angiotensin II in cardiovascular disorders.
Introduction
It was previously thought that the renin-angiotensin sys-
tem (RAS) was a purely endocrine system acting entirely
through the peptide hormone angiotensin II (Ang II) in the
blood. During the past decade, the existence of a tissue
RAS has become more firmly established1'1. Angio-
tensinogen renin, angiotensin converting enzyme (ACE)
and Ang II have all been demonstrated in various tissues
including the heart'2"1'. Use of molecular biology has
proven beyond doubt the extra-renal expression of the
RAS specific messenger RNAs (mRNA) and therefore
the local synthesis of the members of the cascade,
thereby excluding sequestration from the circulation'316'.
Generation of the biologically active peptides can also be
induced in isolated perfused hearts, indicating that it is
independent of the plasma RAS'7'. Both cultured neonatal
rat cardiomyocytes and ventricular fibroblasts have been
shown to express angiotensinogen and renin mRNA as
well as ACE and are able to synthesize Ang II'8-9'.
The existence and functional significance of Ang II
receptors in the heart have also been demonstrated'10"12'.
When radioactive Ang II is injected into the left ventricle
of adult rats, it localizes preferentially around the nucleus
of cardiac muscle cells, suggesting the existence of Ang II
nuclear binding sites'131. More recently, Ang II binding sites
have been observed in purified liver nuclei'1413' and have
been shown to modulate the transcription of mRNA for
renin and angiotensinogen, suggesting a role of Ang II in
intracellular regulation of the RAS116'.
These findings therefore clearly indicate that there is
intra-cardiac synthesis of RAS components, and clinical
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evidence for an active RAS in the heart has been obtained
from the effective use of ACE inhibitors in the treatment
of congestive heart failure, heart hypertrophy, coronary
atherosclerosis, myocardial infarction and post-infarction
remodelling'3-617-1"
The purpose of this short review is to summarize the pre-
sent knowledge on the Ang II receptor in the heart and to
discuss the potential role of the Ang II receptor subtypes in
the pathophysiology of heart diseases.
Location and characterization of Ang II receptors in the
heart: animal studies
The first radioligand binding report using Ang II and
19-day old chick embryo cardiocytes was made by Moore
in WSO120'. Since then, Ang II binding sites have been iden-
tified in rabbit, guinea-pig, bovine, chicken, rat, pig, mon-
key and human heart121'. In the early studies, one or two
binding sites with high and low affinity were reported and
guanine nucleotides modulated their affinity, suggesting a
coupling with a G-protein'10'. It is only recently that two dif-
ferent receptor subtypes, called AT, and AT2 have been
described using selective ligands'22-23'. Losartan (DuP 753)
binds specifically to the AT, receptor, whereas CGP 42112
and PD123177 have a high affinity for the AT2 receptor.
AT, and AT2 are essentially distinguished by two other
characteristics: firstly, sensitivity to reducing agents like
dithiothreitol (DTT) which decrease binding of Ang II by
the AT, receptor, whereas binding by the AT2 receptor is
increased'24'. Secondly, in contrast to the AT, subtype,
GTPyS has been shown to have no effect on the AT2 bind-
ing characteristics, thus indicating a lack of coupling of this
receptor to a G protein'25'.
Using the same criteria, two receptor subsets were iden-
tified in rabbit ventricular membrane'26'. The AT, subtype
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has a Kd of 31 nM for losartan, whereas the AT2 subtype
shows a Kd of 0-5 nM for CGP 42112. The two receptor
populations have an almost identical affinity for Ang II (1-5
and 1 -2 nM for the AT, and AT2, respectively) and the ratio
of AT,/AT2 is nearly equal (60:40). Chang and Lotti con-
firmed this ratio in the rabbit heart and also that of the
monkey*27'. In an undefined strain of rat, however, these
authors reported a high proportion of AT, receptor sub-
type (90%), suggesting an heterogeneity amongst
species'28'. In contrast, equal proportions of AT, and AT2
were seen in 'in situ' binding assay on tissue sections
obtained from fetal, neonatal and adult Sprague Dawley
rats'291. Interestingly, the density of the receptor was at least
twice as high in the neonatal as in the adult heart, indicat-
ing that the receptor expression is developmentally regu-
lated. Myocytes, freshly isolated from neonatal rats
through a Percoll column, express roughly 20% of the AT2
receptor subtype. The AT2 receptors, however, seem to dis-
appear rapidly during primary culture (Rogg, Ramjou6
and Whitebread, unpublished observation). This obser-
vation is important in the interpretation of results obtained
from such culture preparations for detection and quanti-
tation of Ang II receptors subtypes.
As in other tissues'241, the AT, and AT2 receptor subtypes
in the heart can be characterized by their different sensi-
tivities to disulfide reducing agents, the binding of the AT2
receptor being increased and that of AT, decreased after
DTT treatment'26'.
Cellular location in the heart
It is known that the heart is a heterogeneous tissue and
cardiomyocytes occupy nearly 76% of the structural space,
but represent only one third of all cells'30'. The remaining
cells (2/3) are made up from fibroblasts, endothelial cells,
vascular smooth muscle cells, macrophages, nerve cells,
and specialized cells of the conduction system. Membrane
binding assays cannot determine whether the AT, and
AT2 receptor are co-expressed in the same cells, or if the
two receptor subtypes are expressed in different cells.
Knowledge of where and via which receptors Ang II exerts
its cardiac action could give important clues as to the func-
tion of the receptor subtypes. Early studies have shown low
density binding in the myocardium, moderate to high den-
sity binding throughout the conduction system, and high
density binding in the autonomic nervous system'31"33'.
Iwami et a/.'34' separated cardiomyocytes and non-
myocytes from neonatal rat heart and evaluated the AT,
mRNA levels in these fractions. Interestingly, the AT,
receptor mRNA was primarily located in non-cardiomy-
ocyte fractions in adult rat heart'34'. We have performed in
vitro binding to localize Ang II receptors at the light micro-
scopic level on sections of rabbit heart using film or emul-
sion autoradiography for detection. As illustrated in Fig. 1,
a high density of Ang II receptors was detected in nerve
cells next to intramural coronary arteries. Subtype-selec-
tive agents have been used in competition with radiola-
Figure 1 Dark-field micrographs showing the location of Ang II receptor subtypes in rabbit heart parasympathetic nerve
cells situated next to intramural coronary arteries. Adjacent sections were incubated with 0-25 nM IBI-[Sar', He"] Ang II in
the absence (a), or presence of 1 /iM Ang II (b), 100 nM CGP42112 (c) or 1 /JM losartan (d). Binding was visualized using
the coverslip emulsion autoradiograhy method'631. All Ang II receptors are of the AT, subtype, (bar = 100 fim).
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belled [Sar'.IIe8] Ang II to determine the receptor subtype
expressed in the parasympathetic nerves. The binding was
totally inhibited by the AT, antagonist losartan and not by
the AT2 competitor CGP42112, indicating that the nerve
cells contain only the AT, receptor subtype. Subtyping has
also been performed in the conduction system of the rat
heart. Saavedra et al.[35] detected only the AT, receptor sub-
type in both sinoatrial (SA) and atrioventricular (AV)
nodes, whereas Sechi et al. found the same ratio of AT! to
AT2 in cardiac tissue and in the myocardium of the rat with
a greater density of the receptor in AV rather than in SA
nodes!29'.
Ang II receptors in the human heart
Binding studies have also been performed in human car-
diac tissue and the presence of both the receptor subtypes
observed in rat and rabbit heart has been confirmed1361.
Atria, right and left ventricles from five normal people
not eligible as heart donors and right atrial tissues from 35
patients undergoing heart surgery, were investigated. In
normal heart tissue, the density of the receptor (mean
SEM) decreased from the right atrium (323 ± 35 fmol/mg
protein; n = 5) to the left ventricle (118 ± 30; n ± 5). The
amount of Ang II receptor measured in this study is signif-
icantly higher than that which was reported earlier for
human heart by Urata et a/.'32'. The difference may be due
to the tissue collection procedure and the preparation of
the membrane. The two different subtypes can be distin-
guished, the AT, receptor accounting for 60% in both
chambers. In right atrial membranes from pathological
hearts, Ang II receptors (mean ± SEM; n = 35) were pre-
sent in high density (406 ± 60 fmol/mg protein) and affin-
ity (1 -4 ± 0-18 nM). The two different subtypes (Fig. 2) were
also detected with a relative abundance of AT, receptor, of
33 ± 2% (mean ± SEM; n = 35). These results indicate a
considerable change in the AT,/AT2 ratio between normal
and diseased hearts157'.
The Ang II receptors and cardiac function
There is no doubt as to the implications of Ang II in post-
infarction remodelling, in cardiac hypertrophy and in heart
failure. However, the Ang II receptor subtypes involved
remains to be established.
The potential relationship of the Ang II receptor sub-
types to parameters of cardiac function was investigated in
the right atria of 35 patients undergoing coronary bypass
surgery and/or valve replacement. The left ventricular ejec-
tion fraction was measured before, and right and left atrial
pressure were recorded during surgery. There was no cor-
relation between any of the measured cardiac functions
and total Ang II receptor density or affinity. However,
the percentage of AT] receptors was significantly higher in
the atria of patients with normal right atrial pressure
(r = 0-901; P < 0001) and left ventricular ejection fraction
(r = 0-74; P < 0001) while the percentage of the AT2
receptor was positively correlated with the levels of left
atrial pressure (r = 0-853; P < 0-001). Hence, the ratio of
AT, and AT2 receptors in atria shows a good correlation

















Figure 2 Inhibition of 125I-Ang II binding to membranes of
human atria and quantitation of the receptor subtypes. The radio-
ligand and varying amounts of unlabelled Ang II or subtype selec-
tive ligands were incubated with the membrane fraction (5 /ig of
protein), and the receptor binding studies were performed and
quantitated as described1261. The solid circles represent the values
obtained from the tissue of one patient determined in duplicate.
The total receptor density was 405 ± 60 fmol"'mg protein (mean
± SEM; n = 35) and the Kd value for Ang II was 1-4 nM. The pro-
portions of Ang II receptor subtypes were determined in compe-
tition binding experiments by their sensitivity to subtype selective
concentrations of losartan (formerly named DuP 753; selective for
the AT, subtype) and CGP 42112 (selective for AT2). The CGP
column represents the data obtained in the presence of CGP 42112
(0-3 //M). The white area, the resistant section, represents the AT,
receptors and the hatched area the sensitive section represents the
AT2 receptors. DuP shows the inverse experiment using losartan
(3 /jm) where the resistant section represents the AT2 receptors
(hatched area) and the sensitive section the AT, receptors (white
area). The mean of these two cross-experiments was used to cal-
culate the AT,/AT2 ratio (33 ±2/66 + 2; mean SEM; n = 35). In
the patient represented in this Fig. the ratio was 37/63.
respect to the absolute density of AT, receptors, a signifi-
cant difference was found in atrial tissue from patients with
normal vs pathological left ventricular function (Fig. 3).
Similarly, the relative abundance (mean ± SEM) of AT,
receptor was lower in left ventricles of heart from cardiac
transplant recipients (40 ± 4; n = 9) compared with normal
hearts which were not used for transplantation (60 ± 4;
n = 5), suggesting a selective down-regulation of the AT,
receptor in these patients From these data the proposal
Normal Pathological
Figure 3 The proportion of AT,(D) and AT2(H) receptors in
atrial membranes of patients with normal ejection fraction
(EF > 60%; n = 8) and pathological left ventricular function
(EF < 49%; n = 16). The asterix indicates a significant difference
(P < 0-05) in the AT, receptor density (fmol~I.mg protein).
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can be put forward that the more severe the heart failure,
the lower the AT] and the higher the AT2 receptor propor-
tion or density1381. The same observation has been made in
rats hearts after aortic banding in which cardiac AT, recep-
tors are down-regulated in pressure-overloaded left ven-
tricular hypertrophy139'.
Our working hypothesis described above could be
challenged in the light of some studies reported in the
literature. For example, in contrast to previous observa-
tions in human and rat heart, an up-regulation of both
AT! and AT2 receptor expression was reported in rat
cardiac hypertrophy'1'0-411. A threefold increase in ventricu-
lar AT1A mRNA levels, an isoform of the AT! receptor
expressed in vascular tissues'42', and 1-7-fold rise in Ang II
receptor densities were observed in spontaneously (SHR)
and renovascular hypertensive (WKY) rats'4041'. In these
studies, the proportion of AT, and AT2 receptors measured
with selective ligands was nearly equal and remained
unchanged during the progression of the hypertrophy.
Regression completely reversed the increased levels of
mRNA and receptor density to the control levels. We
cannot yet explain the discrepancy between human
and these animal studies but it may be related to the
experimental models.
An increased density of the Ang II receptors was also
observed in isolated myocytes obtained from rat hearts
with myocardial infarction after coronary artery ligation'43'.
Only the AT! receptor subtype was detected, but as has
been previously stated, the AT2 subtype rapidly disappears
during the primary culture (Rogg et al. unpublished data)
and so the effect of the culture conditions must be taken
into account.
The role of the Ang II receptor in cardiac
pathophysiology
Many reports suggest that the AT, receptor subtype
plays a major role in cardiac pathophysiology. The Ang II
receptor antagonist L 158809 administered to rats in drink-
ing water for 7 days after coronary ligation reduced left
ventricular systolic and end diastolic pressure as well as the
length and diameter of left ventricular myocytes'43'. In the
same model, early treatment with subcutaneous losartan
(15 mg.kg~'.day~') only slightly reduced DNA synthesis
but, in contrast to captopril, did not affect cardiac out-
putl44'. This suggests that the effects of captopril may not be
entirely dependent on AT, receptor-mediated mecha-
nisms. Losartan administered to 3-day-old piglets
decreased the left ventricle/body weight ratio and
RNA/DNA ratio in the left ventricle, indicating the
involvement of theATi receptor in the growth of the heart
after birth'454*1. Losartan also inhibits the Ang II-induced
hypertrophy of cardiac myocytes and hyperplasia of car-
diac fibroblasts'47481. The implication of the AT, receptor in
reactive growth processes after myocardial infarction has
been documented'49'. For example, losartan blocks the in-
duction by Ang II of immediate-early genes (c-fos, c-myc,
c-jun), late fotal genes (a-actin, ANP receptor genes)
and growth factor genes TGF/J)'50'. Finally, the positive
inotropic response to Ang II in isolated papillary muscles
from rabbit heart'51' or right and left atria from guinea-
pigs'52' were competitively antagonized by losartan. There
was no apparent functional consequence of Ang II interac-
tion with the AT2 receptor. Therefore, most, if not all, of
the beneficial effects observed with ACE inhibitors on
haemodynamic parameters and cardiac hypertrophy will
probably be seen after treatment with ATi receptor antag-
onists.
The involvement of the AT2 receptor in cardiac patho-
physiology remains largely ill defined at the moment.
However, Daemen et al. using the model of coronary
ligation in the rat have recently described an effect of
AT2 receptor blockade'531. After infusion of PD 123319,
a specific AT2 antagonist, for 2 weeks by subcutaneous
implanted osmotic minipumps at a dose of Smg.kg^.day"1,
the cumulative BrdU labelled fraction in the non-infarcted
septum was significantly decreased by 60%. This result sug-
gests that the AT2 receptor subtype is involved in the regu-
lation of DNA synthesis in interstitial cells. The cell-type
involved, e.g. fibroblast or endothelial cells, is currently
under investigation.
Conclusion
The importance of the RAS in cardiovascular disease,
both experimentally and clinically, has been well illustrated
by the beneficial effect observed with ACE inhibitors on
inhibiting the development of atherosclerosis, cardiac
hypertrophy and remodelling. The Ang II AT, receptor
antagonists discussed here represent a new class of
drugs which appear to have the same indications as the
ACE inhibitor but possibly a better tolerability profile'54'.
Their efficacy in human subjects has been proven in
hypertension but has still to be demonstrated for other
indications.
The existence of two Ang II receptor subtypes in the
heart has been demonstrated. As reported previously,
blockade of the AT, receptor alone, in animal and in man,
is accompanied by a compensatory increase of circulating
Ang II'55-581. This may result in Ang II exerting some hith-
erto unknown, possibly unwanted effects via the
unblocked non-AT, receptors. The functional importance
and clinical relevance of recently identified receptors other
than ATi and AT2, such as AT3 and AT*'59-60' is not yet
known and therefore requires further investigation.
There are some conflicting data in the literature con-
cerning the implication of the AT2 receptor in cardiovascu-
lar disease. This leads one to question the validity of the
various animal and in vitro models. It appears, however,
that there is a 'balance' between the number and distribu-
tion of AT, and AT2 receptors in the human heart suggest-
ing a role for AT2 in the pathophysiology of cardiac
dysfunction'61'.
Recent advances in the treatment of cardiovascular
disorders have paralleled our increase in knowledge
about the RAS. With the cloning of both AT, and AT2
receptors Is2-64' and the availability of potent and selective
AT, and AT2 blockers, tools are now available to under-
stand better the biology of Ang II and most probably to
open new therapeutic perspectives.
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